Creatine Monohydrate

ApprovedSmall molecule

Creatine Monohydrate is one of 159 small molecule programs targeting Amyotrophic Lateral Sclerosis. It is currently in Approved.

Indications

Total Trials

Active Trials

158

Competitors

Pipeline

Status by Indication[3][1]

Indication

Amyotrophic Lateral SclerosisActive, not recruiting

Inflammatory Bowel DiseaseActive, not recruiting

Peripheral Artery DiseaseActive, not recruiting

Duchenne Muscular DystrophyActive, not recruiting

Type 2 DiabetesActive, not recruiting

Amyotrophic Lateral SclerosisPhase 2

Active, not recruiting

Inflammatory Bowel DiseasePhase 1

Active, not recruiting

Peripheral Artery DiseasePhase 2

Active, not recruiting

Duchenne Muscular DystrophyPhase 3

Active, not recruiting

Type 2 DiabetesApproved

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Creatine Monohydrate

MMassachusetts General Hospital

Approved

1 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

NOVOLIN R

Novo Nordisk

Preclinical

5 5

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 6

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 7

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 8

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 9

Cecon

MMcGuff Pharmaceuticals, Inc.

Preclinical

1 10

Forxiga

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Huntington's Disease4 trials

Creatine Safety & Tolerability in Huntington's Disease

Completed·MMassachusetts General Hospital·Phase 2·NCT01412151·10 enrolled

Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study

Completed·MMassachusetts General Hospital·Phase 2·NCT01411150·38 enrolled

Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)

Terminated·MMassachusetts General Hospital·Phase 3·NCT00712426·553 enrolled

Show 1 more trial

Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability

Completed·MMassachusetts General Hospital·Phase 2·NCT01411163·24 enrolled

Amyotrophic Lateral Sclerosis2 trials

Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis

Unknown status·TThe Avicena Group·Phase 3·NCT00069186·107 enrolled

Creatine for the Treatment of Amyotrophic Lateral Sclerosis

Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 2·NCT00070993·110 enrolled

Methamphetamine Use2 trials

A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users

Completed·PPerry Renshaw·Phase 4·NCT02192931·65 enrolled

Creatine for Depressed Male and Female Methamphetamine Users

Recruiting·—·Phase 3·NCT02568878·29 enrolled

Duchenne Muscular Dystrophy2 trials

Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy

Completed·CCooperative International Neuromuscular Research Group·Phase 2/3·NCT00016653·48 enrolled

A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)

Completed·NNational Center for Research Resources (NCRR)·Phase 3·NCT00018109

Depression2 trials

Creatine Monohydrate Use for Preventing Altitude Induced Depression

Withdrawn·MMike O'Callaghan Military Hospital·Phase 4·NCT03433651

5-HTP and Creatine for Depression

Completed·UUniversity of Utah·Phase 2·NCT04395183·43 enrolled

8 more indications

Type 2 Diabetes1 trial

Creatine for Treatment of Depression Associated With Type 2 Diabetes

Withdrawn·UUniversity of Utah·Phase 4·NCT03202095

Female1 trial

Open-Label Creatine Study for Female Meth Users

Terminated·PPerry Renshaw·N/A·NCT02189915·14 enrolled

Peripheral Artery Disease1 trial

Creatine Use and Muscle Stretching in Peripheral Artery Disease

Completed·FFlorida State University·Phase 2·NCT04471792·13 enrolled

Resistance1 trial

Effects of High-velocity Resistance Training and Creatine Supplementation in Healthy Aging Males

Unknown status·UUniversity of Regina·Phase 2·NCT03530202·40 enrolled

Inflammatory Bowel Disease1 trial

Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)

Withdrawn·UUniversity of Colorado, Denver·Phase 1·NCT02463305

Adolescent1 trial

Creatine Treatment for Female Adolescents With Depression Who Are Non-Responders to Fluoxetine or Escitalopram

Completed·UUniversity of Utah·Phase 2·NCT00851006·13 enrolled

Methamphetamine1 trial

Creatine as a Treatment Option for Depression in Methamphetamine Using Females

Completed·PPerry Renshaw·Phase 4·NCT01514630·14 enrolled

Unspecified1 trial

Creatine Safety and Tolerability in Premanifest HD: PRECREST

Completed·MMassachusetts General Hospital·Phase 2·NCT00592995·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for Creatine Monohydrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Creatine Monohydrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Creatine Monohydrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMassachusetts General Hospital

Creatine Monohydrate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Huntington's Disease4 trials

Amyotrophic Lateral Sclerosis2 trials

Methamphetamine Use2 trials

Duchenne Muscular Dystrophy2 trials

Depression2 trials

Type 2 Diabetes1 trial

Female1 trial

Peripheral Artery Disease1 trial

Resistance1 trial

Inflammatory Bowel Disease1 trial

Adolescent1 trial

Methamphetamine1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News